Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia

INTRODUCTION: Clofarabine monotherapy at a dose of 52 mg/m(2) per day was approved in the USA in 2004 for the treatment of relapsed or refractory acute lymphoblastic leukemia (R/R ALL) in patients aged 1–21 years after at least two prior regimens. To address a post-marketing requirement for addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeha, Sima, Goto, Hiroaki, Baruchel, André, Boëlle-Le Corfec, Emmanuelle, Geffriaud-Ricouard, Christine, Pieters, Rob, Shin, Hee Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611855/
https://www.ncbi.nlm.nih.gov/pubmed/37819554
http://dx.doi.org/10.1007/s12325-023-02696-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611855/
https://www.ncbi.nlm.nih.gov/pubmed/37819554
http://dx.doi.org/10.1007/s12325-023-02696-7

Ejemplares similares